Results 131 to 140 of about 27,891 (313)
Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient? [PDF]
Purpose To evaluate the variables influencing the therapeutic choice toward oral versus subcutaneous semaglutide in a cohort of diabetic subjects.Methods We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University ...
Baronti W. +6 more
core +1 more source
Obesity, EarlyView.ABSTRACT Objective This study aimed to describe parental communication with children around obesity management medications (OMMs) and child, parent, and family factors associated with communication. Methods Parents (N = 211; 80% mothers; 89% White) prescribed OMMs at a medical center participated in a survey about communication with children about OMM ...
Keeley J. Pratt +3 more
wiley +1 more source
Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications
Obesity, EarlyView.ABSTRACT Objective This study compared changes in health care costs and use across cohorts initiating four obesity medications (OMs). Methods Commercial insurance claims were used to identify new initiators of phentermine (n = 136,788), phentermine‐topiramate‐ER (n = 13,888), naltrexone‐bupropion‐SR (n = 28,712), or liraglutide (n = 49,266) for obesity.
Kristina H. Lewis +10 more
wiley +1 more source
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials [PDF]
Aims/hypothesis: We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus.
Avgerinos, Ioannis +9 more
core +2 more sources
Obesity, EarlyView.ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez +10 more
wiley +1 more source
Long-term Effect of Oral Semaglutide on Glycemic Control: An Extended Observational Study over Two Years from Baseline [PDF]
The aim of this study is to investigate the long-term effect of oral semaglutide on glycemic control. The effect on glycemic control of switching from a DPP4 inhibitor to oral semaglutide was examined in an extended period of 2 years from baseline in ...
Hara, Kenji +4 more
core +1 more source
Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency
Obesity, EarlyView.ABSTRACT Setmelanotide, a melanocortin 4 receptor (MC4R) agonist, is a promising pharmacological treatment option for people with rare monogenic obesity conditions affecting the leptin‐melanocortin signaling pathway, including proprotein convertase subtilisin/kexin type 1 (PCSK1) gene mutations.
Ellina Lytvyak +2 more
wiley +1 more source
Health Economics ReviewBackground To estimate the long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin as an add-on therapy for type 2 diabetes patients inadequately controlled on metformin in China, to better inform healthcare decision making.
Shuyan Gu +6 more
doaj +1 more source
Pediatric Investigation, EarlyView.Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil +2 more
wiley +1 more source